Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Completed 2

Sponsor Class

OTHER 20OTHER_GOV 3INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1Classical hematology 1

Conditions

Breast Neoplasms 170Neoplasms 129Prostatic Neoplasms 92Lung Neoplasms 82Colorectal Neoplasms 80Pancreatic Neoplasms 38Leiomyoma 37Carcinoma, Hepatocellular 36Lymphoma, Follicular 35Carcinoma, Non-Small-Cell Lung 31Neoplasm Metastasis 27Skin Neoplasms 26Liver Neoplasms 26Colonic Neoplasms 26Uterine Cervical Neoplasms 25Multiple Myeloma 23Head and Neck Neoplasms 22Glioblastoma 22Barrett Esophagus 21Polycystic Ovary Syndrome 19Brain Neoplasms 18Urinary Bladder Neoplasms 17Polyps 16Ovarian Neoplasms 15Esophageal Neoplasms 15Stomach Neoplasms 14Squamous Cell Carcinoma of Head and Neck 14Rectal Neoplasms 14Carcinoma, Squamous Cell 14Carcinoma, Basal Cell 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase NA × INDUSTRY × Treatment Adherence and Compliance × Clear all
NCT05260203 2024-11-06

MargheRITA

Advice Pharma Group srl

Phase NA Completed
124 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Treatment Adherence and Compliance, Amyloidosis, Anemia, Refractory, with Excess of Blasts, Hodgkin Disease, Multiple Myeloma, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Neoplasms, Plasma Cell

NCT05286632 2024-11-06

KidneYou - Innovative Digital Therapy

Advice Pharma Group srl

Phase NA Completed
210 enrolled
Genitourinary

Nephronophthisis, familial juvenile, Treatment Adherence and Compliance, Albuminuria, Diabetes Mellitus, Hypertension, Polycystic Kidney Diseases, Tuberous Sclerosis, Renal Insufficiency, Chronic, Kidney Diseases, Cystic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡